Published in Cancer J Sci Am on January 07, 1998
Intraoperative lymphatic mapping and sentinel lymphadenectomy: community standard care or clinical investigation? Cancer J Sci Am (1998) 1.04
Ultrastaging of lymph node in uterine cancers. J Exp Clin Cancer Res (2010) 0.98
Issues affecting molecular staging in the management of patients with melanoma. J Cell Mol Med (2007) 0.92
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA (1996) 4.13
Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol (1999) 3.74
Human beta-nerve growth factor gene sequence highly homologous to that of mouse. Nature (1983) 3.17
Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg (1998) 2.90
Implementation of new surgical technology: outcome measures for lymphatic mapping of breast carcinoma. Ann Surg Oncol (1999) 2.36
Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation (2001) 2.24
The orderly progression of melanoma nodal metastases. Ann Surg (1994) 2.16
Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer (1998) 2.11
Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma of the lower extremity. Plast Reconstr Surg (1999) 2.02
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol (2000) 1.98
In support of sentinel node biopsy as a standard of care for patients with malignant melanoma. Dermatol Surg (2000) 1.95
Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol (1999) 1.68
Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol (2001) 1.66
Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg Oncol (1998) 1.64
Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA (1998) 1.62
Detection of submicroscopic lymph node metastases in patients with melanoma. Arch Surg (1991) 1.61
Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. Surgery (1984) 1.59
Sentinel-lymph-node biopsy for breast cancer--not yet the standard of care. N Engl J Med (1998) 1.54
Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer (1998) 1.54
The effects of postinjection massage on the sensitivity of lymphatic mapping in breast cancer. J Am Coll Surg (2001) 1.53
Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node. Ann Surg Oncol (1999) 1.50
Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery (1995) 1.49
Malignant melanoma and pregnancy. Cancer (1985) 1.47
Influence of physician communication on newly diagnosed breast patients' psychologic adjustment and decision-making. Cancer (1994) 1.46
Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol (1994) 1.43
Analysis of residual cancer after diagnostic breast biopsy: an argument for fine-needle aspiration cytology. Ann Surg Oncol (1995) 1.42
Cutaneous lymphatic drainage in patients with grossly involved nodal basins. Ann Surg Oncol (1999) 1.42
Decreased mortality of severe acute pancreatitis after proximal cytokine blockade. Ann Surg (1995) 1.41
Monoamine oxidase and catechol-O-methyltransferase activity in hamster and rat insulinomas. Diabetologia (1979) 1.41
Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer (1996) 1.41
Panic disorder and depression in female alcoholics. J Clin Psychiatry (1988) 1.40
Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. J Am Acad Dermatol (1998) 1.38
Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol (2000) 1.38
Randomized prospective evaluation of a novel technique for biopsy or lumpectomy of nonpalpable breast lesions: radioactive seed versus wire localization. Ann Surg Oncol (2001) 1.38
Chlorhexidine. An adjunct to periodontal therapy. J Periodontol (1986) 1.37
Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg (1995) 1.35
Lethal "thin" malignant melanoma. Identifying patients at risk. Ann Surg (1988) 1.30
Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg (1991) 1.28
Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg (2001) 1.28
Touch preparation cytology of breast lumpectomy margins with histologic correlation. Arch Surg (1991) 1.27
Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg (1983) 1.26
Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery (2001) 1.26
Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg (1994) 1.16
The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer (2000) 1.15
The role of sentinel lymph node biopsy in breast cancer. J Am Coll Surg (1999) 1.14
Timing of tumor necrosis factor antagonism is critical in determining outcome in murine lethal acute pancreatitis. Surgery (1996) 1.13
Selective lymphadenectomy in patients with Merkel cell (cutaneous neuroendocrine) carcinoma. Ann Surg Oncol (1997) 1.12
Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol (2001) 1.10
Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg (1996) 1.09
Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol (2013) 1.09
Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol (2001) 1.08
Metastatic malignant melanoma with an unknown primary. Surg Gynecol Obstet (1983) 1.06
Cost analysis of sentinel lymph node biopsy as an alternative to elective lymph node dissection in patients with malignant melanoma. Surg Oncol Clin N Am (1999) 1.06
Lymphoscintigraphy in malignant melanoma. Ann Plast Surg (1992) 1.04
Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Res (1995) 1.04
An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol (2000) 1.03
Malignant melanoma arising during pregnancy. A study of 100 patients. Ann Surg (1990) 1.03
Scar assessment: current problems and future solutions. J Burn Care Rehabil (1999) 1.02
Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma. J Am Acad Dermatol (1997) 1.01
Bleomycin-mediated electrochemotherapy of basal cell carcinoma. J Am Acad Dermatol (1996) 1.01
Malignant melanoma in black American and white American populations. A comparative review. JAMA (1982) 0.99
Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol (1996) 0.99
Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding. J Med Chem (1986) 0.98
Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol (1998) 0.98
Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer. Annu Rev Med (2000) 0.97
Dysplastic naevi with moderate to severe histological dysplasia: a risk factor for melanoma. Br J Dermatol (2006) 0.96
Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol (2001) 0.96
Clinical approach to neuroendocrine carcinoma of the skin (Merkel cell carcinoma). Cancer Control (2000) 0.95